PWRD yields 0.17% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 8
Combined, PWRD + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PWRD + PFE for your $10,000?
PWRD is a concentrated stock portfolio of companies perceived to drive and benefit from the energy transition to net zero carbon emissions. Using a proprietary framework, the fund screens the broad US equity market to select companies with a strategy to reduce or enable decarbonization at scale. Selection combines a top-down analysis of the economy with a bottom-up, industry-by-industry, and company-by-company assessment. The adviser does not use sustainability ratings or rankings to exclude companies or sectors. As a result, the portfolio may focus on the most carbon-intensive industries in order for the adviser to drive change through its proxy voting guidelines. Such guidelines encourage companies to invest in their employees, communities, customers, and the environment. The adviser has discretion to target specific investment opportunities. Prior to October 13, 2023, the fund was called the Engine No. 1 Transform Climate ETF. Prior to Feb. 3, 2025, the fund had a ticker of NETZ.
Full PWRD Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.